These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Van Woert MH; Sethy VH Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720 [TBL] [Abstract][Full Text] [Related]
4. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735 [TBL] [Abstract][Full Text] [Related]
5. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Thal LJ; Sharpless NS; Wolfson L; Katzman R Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054 [TBL] [Abstract][Full Text] [Related]
6. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa. Thal L; Sharpless N; Wolfson L; Engel J; Katzman R Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459 [No Abstract] [Full Text] [Related]
7. Manipulation of brain serotonin in the treatment of myoclonus. Chadwick D; Jenner P; Harris R; Reynolds EH; Marsden CD Lancet; 1975 Sep; 2(7932):434-5. PubMed ID: 51240 [TBL] [Abstract][Full Text] [Related]
8. Post-hypoxic intention myoclonus treated with 5-hydroxy-tryptophan and an extracerebral decarboxylase inhibitor. Magnussen I; Dupont E; Engbaek F; de Fine Olivarius B Acta Neurol Scand; 1978 Apr; 57(4):289-94. PubMed ID: 307327 [TBL] [Abstract][Full Text] [Related]
9. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Chadwick D; Hallett M; Harris R; Jenner P; Reynolds EH; Marsden CD Brain; 1977 Sep; 100(3):455-87. PubMed ID: 412560 [TBL] [Abstract][Full Text] [Related]
13. L-5-hydroxytryptophan therapy in myoclonus. Van Woert MH; Rosenbaum D Adv Neurol; 1979; 26():107-15. PubMed ID: 316273 [No Abstract] [Full Text] [Related]
14. [Serotoninergic conception of myoclonic syndromes. (Review)]. Levin SL Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(6):797-803. PubMed ID: 224629 [No Abstract] [Full Text] [Related]
15. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Growdon JH; Young RR; Shahani BT Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of serotonin precursors in postanoxic action myoclonus. De Léan J; Richardson JC; Hornykiewicz O Neurology; 1976 Sep; 26(9):863-8. PubMed ID: 1084968 [TBL] [Abstract][Full Text] [Related]
17. Palatal myoclonus: treatment with 5-hydroxytryptophan and carbidopa. Bhatt M; Snow B; Varelas M; Calne D Mov Disord; 1990; 5(4):339-40. PubMed ID: 2259361 [No Abstract] [Full Text] [Related]